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Table I. Baseline characteristics.
Standard treatment H.E.L.P. apheresis + standard treatment
Mean SD Mean SD
No. of patients 115 No. of patients 115
RH ear affected 69 RH ear affected 47
LH ear affected 46 LH ear affected 68
Average age 59.6 34-79 Average age 53.2 32-82
Average before treatment 12 (days) Average before treatment 11 (days)
Total cholesterol 232 ± 32 Total cholesterol 242 ± 37
LDL cholesterol 149 ± 28 LDL cholesterol 158 ± 33
HDL cholesterol 59 ± 18 HDL cholesterol 61 ± 20
Fibrinogen 356 ± 85 Fibrinogen 345 ± 94
Dear Editor-in-Chief,
it is a matter of fact that the aetiology of SShl is still 
unknown, even though many published works tend to 
establish  a  correlation  between  microcirculation  dis-
ease and SShl 1-5. it is also well known that endothe-
lial dysfunction, high levels of haemostatic factors and 
disturbed blood flow are the fundamentals of thrombo-
embolic diseases and can impair the microcirculation of 
the cochlea 6-8. All these features are strongly affected 
by plasmapheresis, in particular by h.E.l.P.-apheresis, 
which is a specific apheretic therapy that acutely de-
creases lDl cholesterol, lp(a), fibrinogen and other 
pro-inflammatory markers like CrP, up to 60% in only 
2 hours 9. After a single h.E.l.P. session, flow-mediated 
vasodilatation improved, significantly 10. h.E.l.P. also 
has an acute beneficial effect on endothelial dysfunction 
and circulating adhesion molecules in patients suffer-
ing from SShl 11. Furthermore h.E.l.P.-apheresis can 
effectively lower plasma and whole blood viscosity, im-
prove erythrocyte elasticity and reduce aggregability 12.
Since 2007 our staff is active with apheresis in the treat-
ment of SShl, thanks to the existing cooperation with the 
Transfusion  Medicine  Unit.  our  first  results  were  pub-
lished on “The laryngoscope” in April 2010 13. This was 
a prospective, randomized, controlled, superiority study 
(difference ≥ 30%), the first conducted in italy in this field, 
approved by the hospital Ethics Committee, in which a to-
tal of 132 patients were admitted to the trial and randomly 
allocated to two different arms; 60 were given standard 
treatment (ST) and 72 were treated with a single h.E.l.P.-
apheresis followed by the standard treatment (h.E.l.P.-
ST). ST consists in an infusion of 10% glycerol (500 ml), 
once a day, for 10 days, and intramuscular administration 
of dexamethasone 8 mg once a day, for 10 days.
The inclusion criteria were patients with a value of lDl–
cholesterol > 120 mg/dl and/or fibrinogen > 320 mg/dl 
and with an acute, one-sided, SShl that occurred not lat-
er than 20 days before the beginning of treatment. (All the 
patients included in the study had a hearing symmetry be-
fore the onset of SShl). in our first study, we considered 
only pure-tone threshold recovery as the main outcome. 
Patients  submitted  to  h.E.l.P.-ST  had  a  recovery  rate 
much higher than those submitted to ST (75% vs. 25% at 
24 hours; 76.4% vs. 23.6% at 10 days).g. Bianchin et al.
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Thanks to these encouraging data, we decided to enlarge 
our experience with plasmapheresis. Following the same 
study design and the same clinical hypothesis of the previ-
ous work, we started a new study, which is the linear evo-
lution of the work previously published on “The laryngo-
scope” in April 2010.
We substantially increased the number of treated patients, 
reaching a total of 230 patients enrolled. 115 were given 
ST and 115 were treated with h.E.l.P.-apheresis followed 
by 10 days of ST (h.E.l.P.-ST). Table i shows the base-
line characteristics of patients.
From a clinical point of view, the new evaluation has been 
enriched with further investigations. We also considered 
speech perception improvement at 24 hours and at 10 
days beyond pure-tone recovery, and we also made a very 
preliminary evaluation on tinnitus score (Thi). The Thi 
was carried out at admission, and at 24 hours and 10 days 
after the end of treatment establish the behaviour of the 
perception of tinnitus from patients.
For all these reasons, we can state that our new contribu-
tion is an extension of the previous one. The increase in the 
number of treated patients had no effect on the percentage 
of pure-tone recovery. Also, the percentage of superiority 
of apheresis plus standard treatment group (h.E.l.P.-ST) 
is close to 30% as seen in Tables ii and iii.
The results of SShl are difficult to analyze; some variables 
are particularly important, while others influence the re-
sults. A correlation between recoveries and the frequencies 
observed must not be ignored. in the h.E.l.P.-ST group, 
we observed recovery in 66.9% of patients at 24 hours and 
Table II. Recovery 24 hours (post) after H.E.L.P. apheresis plus standard treatment or standard treatment.
H.E.L.P.-ST group (post)
(n = 115)
ST group (post)
(n = 115)
p*
Patients with improvement 77 (66.9%) 45 (39.1%) 0.00
Patients with no change 38 (33.1%) 70 (60.9%)
* Chi-square test
Table III. Recovery 10 days (last) after H.E.L.P. apheresis plus standard treatment or standard treatment.
H.E.L.P.-ST group (post)
(n = 115)
n (%)
ST group (post)
(n = 115)
n (%)
p*
Patients with improvement 81 (70.4%) 47 (40.9%) 0.00
Patients with no change 34 (29.6%) 68 (59.1%)
* Chi-square test
Table IV. Recovery of patients according to different frequencies at follow-up 24 hours after treatment (post) and 10 days after treatment (last). Paired 
T-test p = 0.001.
Tonal Threshold 250 Hz 500 Hz 1000 Hz 2000 Hz 4000 Hz
H.E.L.P.+ST Group
115 pz (post)
Patients with improvement 69
(60%)
77
(66.9%)
76
(66.1%)
56
(48.7%)
62
(53.9%)
Patients with no change 46
(40%)
38
(33.1%)
39
(33.9%)
59
(51.3%)
53
(46.1%)
ST Group
115 pz (post)
Patients with improvement 45
(39.1%)
45
(39.1%)
42
(36.5%)
35
(30.4%)
45
(35.6%)
Patients with no change 70
(60.9%)
70
(60.9%)
73
(63.5%)
80
(69.6%)
74
(64.3%)
H.E.L.P.+ST Group
115 pz (last)
Patients with improvement 75
(65.2%)
81
(70.4%)
76
(66.1%)
63
(54.8%)
68
(59.1%)
Patients with no change 40
(34.8%)
34
(29.6%)
39
(33.9%)
52
(45.2%)
47
(40.8%)
ST Group
115 pz (last)
Patients with improvement 44
(38.3%)
47
(40.9%)
43
(37.4%)
39
(33.9%)
43
(37.4%)
Patients with no change 71
(61.7%)
68
(59.1%)
72
(62.6%)
76
(66.1%)
72
(62.6%)
H.E.L.P. + ST Group: H.E.L.P. apheresis + Standard Treatment Group; ST Group: Standard Treatment Group.h.E.l.P.-apheresis in SShl
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70.4% at 10 days after treatment. only 33.1% at 24 hours 
and 29.6% of the patients at 10 days showed no change. in 
the ST group, recovery was 39.1% at 24 hours and 40.1% 
at 10 days, while 60.9% at 24 hours and 59.1% at 10 days 
had no change. next we examined in detail the recovery 
of patients for each frequency. Table iV shows recovery of 
patients according to different frequencies at different fol-
low-up times (24 hours and 10 days) for the two different 
groups. For the h.E.l.P.-ST group, the improvement was 
statistically significant at both the first and second follow-
ups and for all frequencies. (Paired T – test; p = 0.001).
Table V shows the absolute values of the mean pure-tone 
recovery in decibels according to frequency; higher val-
ues were seen for the h.E.l.P.-ST group compared to the 
ST group for all frequencies. The recovery absolute val-
ues vary, in the post follow-up, for the h.E.l.P.-ST group 
from 12.7 dB at 500 hz to 8.6 dB at 4000 hz, compared 
to 8.1 dB at 500 hz to 4.1 dB at 2000 hz in the ST group 
(p < 0.05; p < 0.05). in the last follow-up, the trend is 
similar with a range from 15.1 dB at 500 hz to 11 dB at 
4000 hz for the h.E.l.P.-ST group, while the ST group 
showed a range from 9.3 dB at 500 hz to 5.3 at 2000 hz 
(p < 0.05; p < 0.05). The analysis of the results of the 
h.E.l.P.-ST group compared to ST group allow for the 
consideration that h.E.l.P.-apheresis is the element re-
sponsible for the difference.
Mean  speech  perception,  measured  by  the  sound  level 
at which patients could recognize 50% of the presented 
test words, was 10.3 dB after 24 hours in the h.E.l.P.-ST 
group and 6.1 dB in the ST group (p < 0.05). Moreover, 10 
days after treatment mean speech perception was signifi-
cantly better (p < 0.05) in the h.E.l.P.-ST group (12 dB) 
with respect to ST group (7.3 dB; Table Vi).
our preliminary data support the hypothesis that h.E.l.P.-
apheresis is also effective in treatment of tinnitus 14. We 
collected a small amount of data, but the results obtained 
from Thi seem to be encouraging, with a recovery of two 
points in the 58% of the patients in the h.E.l.P.-ST group, 
with respect to ST group where 32% of the patients pre-
sented a recovery of two points.
our intention was to offer a further contribution to our first 
publication in terms of clinical evidence, including speech 
perception by measuring and tinnitus score improvement. 
in our opinion, as already reported by others 15 16, the pa-
tient’s quality of life seems to be better in those subjects 
submitted to apheresis, thanks to quicker clinical improve-
ment  and  good  tolerability.  our  new  data  suggest  that 
h.E.l.P.- apheresis is a safe and effective treatment for 
SShl. in particular, in a specific group of patients, with 
alterations in lDl-cholesterol and fibrinogen, h.E.l.P.-
apheresis,  represents  an  additional  option  available  for 
clinical treatment of sudden sensorineural hearing loss.
Best regards,
g. Bianchin, g. russi, n. romano, P. Fioravanti
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